UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

Antimicrobial Agents and Chemotherapy, 2010-04, Vol.54 (4), p.1484-1491

GUMBO, Tawanda

2010

Volltextzugriff (PDF)

An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

Antimicrobial Agents and Chemotherapy, 2011-01, Vol.55 (1), p.24-34

2011

Volltextzugriff (PDF)

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

The lancet respiratory medicine, 2014-04, Vol.2 (4), p.321-338

2014

Volltextzugriff (PDF)

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis

PloS one, 2020-04, Vol.15 (4), p.e0230927-e0230927

2020

Volltextzugriff (PDF)

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Antimicrobial agents and chemotherapy, 2015-10, Vol.59 (10), p.6337-6343

2015

Volltextzugriff (PDF)

Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis

Nature medicine, 2020-09, Vol.26 (9), p.1435-1443

2020

Volltextzugriff (PDF)

Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions

Nature medicine, 2020-04, Vol.26 (4), p.529-534

2020

Volltextzugriff (PDF)

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

Current opinion in infectious diseases, 2007-12, Vol.20 (6), p.587-591

Gumbo, Tawanda

2007

Volltextzugriff (PDF)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections

IDCases, 2023-01, Vol.33, p.e01843-e01843, Article e01843

2023

Volltextzugriff (PDF)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

Frontiers in pharmacology, 2021-10, Vol.12, p.776969-776969

2021

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

Clinical infectious diseases, 2007-01, Vol.44 (1), p.79-86

2007

Volltextzugriff (PDF)

The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

Antimicrobial Agents and Chemotherapy, 2012-09, Vol.56 (9), p.4806-4815

2012

Volltextzugriff (PDF)

Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.2847-2854

2010

Volltextzugriff (PDF)

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

Journal of antimicrobial chemotherapy, 2017-09, Vol.72 (suppl_2), p.i30-i35

2017

Volltextzugriff (PDF)

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

Current pharmaceutical design, 2011-09, Vol.17 (27), p.2881

2011

Volltextzugriff (PDF)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy

Frontiers in pharmacology, 2022-10, Vol.13, p.1024608-1024608

2022

Volltextzugriff (PDF)

Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse

Communications biology, 2021-06, Vol.4 (1), p.664-664, Article 664

2021

Volltextzugriff (PDF)

Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

Antimicrobial Agents and Chemotherapy, 2007-11, Vol.51 (11), p.3781-3788

2007

Volltextzugriff (PDF)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

International journal of infectious diseases, 2021-04, Vol.105, p.688-694

2021

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3197-3204

2009

Volltextzugriff (PDF)

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

Antimicrobial agents and chemotherapy, 2016-10, Vol.60 (10), p.6374-6376

2016

Volltextzugriff (PDF)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Frontiers in pharmacology, 2021-01, Vol.11, p.616294-616294

2021

Volltextzugriff (PDF)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration

International journal of infectious diseases, 2021-03, Vol.104, p.680-684

2021

Volltextzugriff (PDF)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Frontiers in pharmacology, 2021-06, Vol.12, p.677005-677005

2021

Volltextzugriff (PDF)

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

Antimicrobial Agents and Chemotherapy, 2010-05, Vol.54 (5), p.1728-1733

2010

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(210)

Publikationsform

Artikel
(221)
Berichte
(1)

Sprache

Englisch
(222)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(192)
Life Sciences & Biomedicine
(189)
Humans
(143)
Microbiology
(132)
Infectious Diseases
(97)
Pharmacology & Pharmacy
(92)
Microbial Sensitivity Tests
(63)
Tuberculosis
(56)
Immunology
(54)
Mycobacterium Tuberculosis
(48)
Female
(47)
Male
(47)
Antitubercular Agents - Pharmacokinetics
(44)
Mycobacterium Tuberculosis - Drug Effects
(44)
Antitubercular Agents - Therapeutic Use
(40)
Tuberculosis - Drug Therapy
(40)
Biological And Medical Sciences
(39)
Medical Sciences
(38)
Pharmacology
(36)
Adult
(33)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis

Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients

Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis

Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions

Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore

The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy

Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse

Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

Suchergebnisse filtern